• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      For more information or to register for an event please email dermsuk@abbvie.com

      Join us for Clear Horizons TV series 2 and 3, bringing you updates on SKYRIZI and special guest reports from leading psoriasis clinics.

      Dr. Laura Savage

       Consultant dermatologist, Leeds Centre for Dermatology, Chapel Allerton Hospital 

      Prof. Richard Warren

      Consultant dermatologist and professor of dermatology and therapeutics, Salford Royal NHS foundation trust 

      Dr. Andrew Pink

      Consultant dermatologist and clinical trials lead for adult medical dermatology at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust.

      Dr. Amy Foulkes

      Consultant dermatologist, 
      Salford Royal NHS Foundation Trust

      Dr. Sandy McBride

      Consultant dermatologist, 
      Royal Free London NHS Foundation Trust

      A series of 4 webinars specifically designed to support knowledge and peer sharing for Registrars and new Consultant Doctors within Dermatology.  You’ll hear from experts and peers on a variety of Hot Topics and real world UK SKYRIZI patient case studies.

      Watch Clear Horizons TV series 2 on demand, covering updates on SKYRIZI and special guest reports from leading psoriasis clinics.



      1. SKYRIZI: Summary of Product Characteristics.

      UK-SKZD-210187. Date of preparation: October 2021. 

      SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
      SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
      The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
      SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
      Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
      Study design information can be found on the Study Design page.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com